Arcus Biosciences

About Arcus Biosciences

Arcus Biosciences is a biotechnology company focused on the relentless pursuit of cures for cancer through the design of combination therapies with best-in-class potential. They combine discovery capabilities, accelerated development guided by cancer biology, and partnerships with the cancer community to advance new medicines.

Products & Services

Domvanalimab (Anti-TIGIT):A clinical candidate focused on inhibiting TIGIT to enhance immune response against cancer.

Etrumadenant:A clinical candidate targeting the adenosine axis to modulate immune suppression in cancer.

Casdatifan (HIF-2⍺ Inhibitor):A clinical candidate targeting HIF-2⍺, with initial data showing significant response in metastatic kidney cancer when combined with cabozantinib.

AB801 (AXL Inhibitor):A clinical candidate designed to inhibit AXL for cancer treatment.

domvanalimab

etrumadenant

quemliclustat

zimberelimab

casdatifan

ab598

axl-inhibitor

Specialties

Cancer Combination Therapies Immunotherapy Small Molecule Drug Development Antibody Development Clinical Trials for Cancer Treatments combination cancer therapies small molecules antibodies oncology clinical development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 250000000 MR: - FA: $250 million FAN: 250000000	D: 2025-10-30 FD: 2025-10-30	5 investors
2	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 150000000 MR: - FA: approximately $150 million FAN: 150000000	D: 2025-02-18 FD: 2025-02-18	3 investors
3	RT: Common Stock Offering T: - FT: Common Stock Offering	A: 150000000 MR: - FA: $150 million FAN: 150000000	D: 2025-02-18 FD: 2025-02-18	2 investors
4	RT: Debt T: - FT: Debt	A: 250000000 MR: - FA: Up to $250 million FAN: 250000000	D: 2024-08-27 FD: 2024-08-27	1 investors

Public Offering Latest

2025-10-30

$250.0M

5 investors (Pro only)

Underwritten Offering 2025-02-18

$150.0M

Common Stock Offering 2025-02-18

$150.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Terry Rosen

Chief Executive Officer

J

Juan Jaen

President

B

Bob Goeltz

Chief Financial Officer

R

Richard Markus

Chief Medical Officer

C

Carolyn Tang

General Counsel

Y

Yvonne Gehring

SVP, Human Resources

View 22 more team members with Pro

Unlock Full Team Directory

Recent News